U.S. Markets closed
  • S&P 500

    4,704.54
    +15.87 (+0.34%)
     
  • Dow 30

    35,870.95
    -60.10 (-0.17%)
     
  • Nasdaq

    15,993.71
    +72.14 (+0.45%)
     
  • Russell 2000

    2,363.59
    -13.42 (-0.56%)
     
  • Gold

    1,861.20
    -0.20 (-0.01%)
     
  • Silver

    24.88
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1369
    -0.0006 (-0.0568%)
     
  • 10-Yr Bond

    1.5890
    -0.0150 (-0.94%)
     
  • Vix

    17.59
    +0.48 (+2.81%)
     
  • GBP/USD

    1.3497
    -0.0003 (-0.0216%)
     
  • USD/JPY

    114.3040
    +0.0520 (+0.0455%)
     
  • BTC-USD

    54,738.32
    +515.96 (+0.95%)
     
  • CMC Crypto 200

    1,402.14
    -65.80 (-4.48%)
     
  • FTSE 100

    7,255.96
    -35.24 (-0.48%)
     
  • Nikkei 225

    29,683.09
    +84.43 (+0.29%)
     

Athenex Shares Are Trading Higher On Positive Oral Paclitaxel Data From Solid Tumor Trial

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Athenex Inc (NASDAQ: ATNX) announced data presentation from a Phase 1 study evaluating encequidar (Oral Paclitaxel) in combination with Merck Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in advanced solid malignancies.

  • Paclitaxel is one of the most commonly used chemotherapies.

  • Related Link: Athenex Issues Update On Oral Paclitaxel Application In Metastatic Breast Cancer.

  • Data were presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2021.

  • The dose-escalation phase of the study enrolled 21 patients. Activity data were presented on 17 evaluable patients.

  • Four patients had a partial response, ten patients had stable disease, and three had progressive disease.

  • There were ten non-small cell lung cancer (NSCLC) patients enrolled, of which eight were evaluable for response.

  • Four patients achieved a partial response, and four patients achieved stable disease.

  • All the patients had discontinued previous checkpoint inhibitor therapy due to progressive disease.

  • The maximum tolerated dose of the combination was not reached.

  • Price Action: ATNX shares are up 1.77% at $3.45 during the premarket session on the last check Thursday.

  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21)

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.